Project Grant K22AG095285
Award Date 7/20/26
Completion Date 4/30/29
Dollars Obligated $211K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27514, USA
Similar Awards
- The National Institute on Aging awarded The Washington University $162,000 on March 1, 2026, under the Aging Research program (CFDA 93.866) to identify and characterize new therapy targets in TDP-43 proteinopathies. The award supports research into the mechanisms by which TDP-43 mislocalization results in neuronal death and aims to discover previously unidentified therapy targets that mediate this disease process. TDP-43 pathology is observed across multiple neurodegenerative diseases...
- The National Institute on Aging awarded the University of South Carolina $249,000 on August 15, 2026, under the Aging Research program (CFDA 93.866) to investigate the effects of frontotemporal dementia and amyotrophic lateral sclerosis mutations in RNA-binding proteins on mRNA transport and local translation. The research uses induced pluripotent stem cell-derived neurons with CRISPR-edited FTD/ALS mutations in RNA-binding proteins (TDP-43, FUS, HNRNPA1, HNRNPA2, MATR3, and TIA1) to determine...
- The National Institute on Aging awarded the University of Pennsylvania $6.72 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to develop short RNA therapeutics targeting TDP-43 proteinopathy across amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, limbic-predominant age-related TDP-43 encephalopathy, and chronic traumatic encephalopathy. The recipient will identify and characterize short oligonucleotides that engage the TDP-43 protein,...
- Federal Grant Award Summary The National Institute on Aging awarded Columbia University's Health Sciences Division a $3.21 million Project Grant (CFDA 93.866, Aging Research program) effective August 11, 2025, through July 31, 2029, to conduct research characterizing antigen-specific immune responses in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research will employ an unbiased, multidisciplinary approach to identify self- and non-self peptides and antigens...
- The National Institute on Aging awarded the University of Pennsylvania $425,235 on February 1, 2026, under the Aging Research program (CFDA 93.866) to decode antigen-specific T cells in frontotemporal degeneration. The research investigates the role of CD8+ T cells recognizing cryptic peptides derived from TDP-43 pathology in frontotemporal dementia (FTD). Approximately 50 percent of FTD cases involve TDP-43 pathology that generates cryptic exons; emerging evidence suggests these cryptic...
- The National Institute of Neurological Disorders and Stroke awarded Northwestern University $620,507 on August 14, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the association between TDP-43 dependent disruptions in RNA metabolism and neuronal excitability in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research tests the hypothesis that TDP-43 dependent splicing errors on UNC13A...
- The Project Grant award of $404,058 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to identify novel small molecules that stabilize functional, multimeric forms of the TDP43 protein. The goal is to restore TDP43's native RNA binding and splicing regulation functions, which are impaired in frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other TDP43-related neurodegenerative diseases. The research will leverage high-throughput...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $461,900 Project Grant to Pennsylvania State University on May 1, 2025. The grant, titled "Mechanisms Underlying TDP-43 Dependent Structural Deficits in ALS Muscles", will fund research to study the role of the TDP-43 protein in muscle degeneration associated with Amyotrophic Lateral Sclerosis (ALS). The research aims to uncover the mechanisms by which TDP-43 impacts muscle...
- The National Institute of Neurological Disorders and Stroke awarded the University of Arizona $1,764,771 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the pathological relevance of TDP-43 interactions with translation machinery in neurodegeneration. The award funds research into TDP-43 proteinopathy, which is characterized by mislocalization of tar DNA-binding protein 43 from the nucleus to the...
- The National Institute on Aging awarded Pennsylvania State University, operating as Penn State Milton S. Hershey Medical Center, $479,579 under the Aging Research program (CFDA 93.866) on August 15, 2026, to investigate synaptic and metabolic alterations associated with TDP-43 proteinopathy in amyotrophic lateral sclerosis and frontotemporal dementia. The research identifies how mislocalization of TDP-43 protein from the nucleus to the cytoplasm disrupts synaptic vesicle cycling, RNA processing,...